In this study, fabrication of a composite containing the ordinary Portland cement (OPC) and magnetite (FeO) micro/nanoparticles is reported. In the first stage, the cement paste samples with a fixed 0.2 wt.% FeO additive in four different particle sizes (20-40 nm, 80-100 nm, 250-300 nm, and 1-2 µm) were prepared to check the effect of magnetite size. Magnetite was found to play an effective role in reinforcing cement matrix. The results showed that the cement paste reinforced by magnetite nanoparticles of 20-40 nm size range had the highest compressive, flexural, and tensile strengths compared to those of the other samples reinforced by larger particles. In the second stage, various amounts of the FeO nanoparticles of 20-40 nm size range were added to the cement to evaluate the influence of magnetite amount and find the optimized reinforcement amount. It was revealed that adding 0.25 wt.% FeO nanoparticles of 20-40 nm size range, as the optimal specimen, increased the compressive strength, flexural strength and tensile splitting strength by 23-32, 17-25, and 15-19%, respectively, and decreased the electrical resistance by 19-31%.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028720PMC
http://dx.doi.org/10.1038/s41598-020-59846-yDOI Listing

Publication Analysis

Top Keywords

nanoparticles 20-40 nm
12
20-40 nm size
12
size range
12
cement paste
8
wt% feo
8
feo nanoparticles
8
cement
5
magnetite
5
comparative study
4
study mechanical
4

Similar Publications

Restenosis remains a long-standing limitation to effectively maintain functional blood flow after percutaneous transluminal angioplasty (PTA). While the use of drug-coated balloons (DCBs) containing antiproliferative drugs has improved patient outcomes, limited tissue transfer and poor therapeutic targeting capabilities contribute to off-target cytotoxicity, precluding adequate endothelial repair. In this work, a DCB system was designed and tested to achieve defined arterial delivery of an antirestenosis therapeutic candidate, cadherin-2 (N-cadherin) mimetic peptides (NCad), shown to selectively inhibit smooth muscle cell migration and limit intimal thickening in early animal PTA models.

View Article and Find Full Text PDF

Targeting CHEK1: Ginsenosides-Rh2 and Cu2O@G-Rh2 nanoparticles in thyroid cancer.

Cell Biol Toxicol

January 2025

Department of Radiology, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Heping District, Shenyang, 110004, Liaoning Province, China.

Thyroid cancer (THCA) is an increasingly common malignant tumor of the endocrine system, with its incidence rising steadily in recent years. For patients who experience recurrence or metastasis, treatment options are relatively limited, and the prognosis is poor. Therefore, exploring new therapeutic strategies has become particularly urgent.

View Article and Find Full Text PDF

Fe, Ni, and Cu doped ceria nanoparticles (CeNPs) were prepared with a simple and one-pot hydrothermal synthesis method. We investigated the chemiluminescence (CL) interaction between these NPs and rhodamine B (Rh B) and found that the highest CL intensity was related to the Rh B- Cu doped CeNPs. We assigned that to the higher catalytic property of Cu doped NPs compared to the others.

View Article and Find Full Text PDF

Visual detection of kanamycin with functionalized Au nanoparticles.

Mikrochim Acta

January 2025

Institute of Chemical Engineering, Guangdong Academy of Sciences, Guangzhou, 510665, People's Republic of China.

A simple and rapid colorimetric detection strategy, based on hydrogen bond identification of 6-thioguanine (6-TG) functionalized Au nanoparticles (AuNPs), is proposed for highly selective and sensitive determination of kanamycin (KA). In this strategy, the hydrogen bond interaction between 6-TG and kanamycin induces AuNPs to agglomerate, with a consequent color change of AuNPs from wine red to purple or even blue. The kanamycin concentrations can be quantified by employing UV-vis spectrophotometer.

View Article and Find Full Text PDF

Background: Benefits of neoadjuvant treatment for pancreatic cancer with major vessel invasion has been demonstrated through randomized controlled trials; however, the optimal neoadjuvant treatment strategy remains controversial, especially for radiotherapy. Therefore, we aimed to evaluate the efficacy and safety of neoadjuvant radiotherapy followed by chemotherapy and the optimal time interval to undergo surgery after radiotherapy in (borderline) resectable pancreatic cancer.

Methods: Between 2013 and 2022, patients with (borderline) resectable pancreatic cancer with vessel contact who received 5-fluorouracil with leucovorin, oxaliplatin, and irinotecan or gemcitabine and nanoparticle albumin-bound paclitaxel as initial treatment following surgery were included.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!